Summary
Pfizer Inc. (PFE) has filed an 8-K report detailing modifications to its long-term incentive compensation plans, specifically Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. These changes, approved by the Compensation Committee, aim to enhance employee retention and realign executive compensation with long-term shareholder value, particularly in light of market conditions and the need to recover stock price. The modifications primarily involve extending the performance and settlement periods for these awards by two years. For TSRUs, the settlement date will be pushed back to February 2029 (from 2027) for 2022 grants and February 2030 (from 2028) for 2023 grants. Vesting periods are also extended to the fifth anniversary of the grant date. For PSAs, the three-year performance period will be extended by two years, with performance measured over the final three years of this extended term. This means 2022 PSAs will vest and settle in 2027 (instead of 2025), and 2023 PSAs in 2028 (instead of 2026). The treatment of these awards in the event of an employee's death has also been updated to align with 2024 grant terms. These modifications will be offered through a tender offer (Modification Offer) to eligible employees, including named executive officers.
Key Highlights
- 1Pfizer is modifying 2022 and 2023 Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) to improve employee retention and align compensation with long-term performance.
- 2The modifications extend the settlement and vesting periods for TSRUs by two years, pushing 2022 grants to 2029 settlement and 2023 grants to 2030 settlement.
- 3Performance periods for PSAs are extended by two years, with performance measured over the final three years of the extended term; 2022 PSAs will now settle in 2027 and 2023 PSAs in 2028.
- 4These changes apply to approximately 9,000 active employees, including key named executive officers such as Albert Bourla and David M. Denton.
- 5The company is initiating a 'Modification Offer' via a tender offer to allow eligible employees to elect to accept these revised award terms.
- 6Updated provisions for the treatment of TSRUs and PSAs in the event of an employee's death are being implemented, aligning them with terms in 2024 grants.
- 7The Compensation Committee cited the need to retain key talent and ensure continued alignment of pay with performance as the rationale for these modifications.